To assess the anti-tumor efficacy of GNF-7, FDA approved drug for relapsed/refractory AML [19]—gilteritinib and a highly potent type II FLT3 inhibitor—AC220 [8] were used as a measure of positive drug efficacy. Here, FLT3 is linked to acute myeloid leukemia.